Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation filed Amendment No. 2 to a Schedule 13G with the SEC on November 12, 2026, disclosing a beneficial ownership position in Xenetic Biosciences, Inc. common stock as of July 1, 2026.

Key Highlights

  • Filing entities: Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation jointly filed the amendment.
  • Shares beneficially owned: Each reporting person disclosed beneficial ownership of 55,040 shares of Xenetic Biosciences common stock.
  • Percent of class: The 55,040 shares represent 2.35% of the outstanding class, according to the filing.
  • Voting and dispositive power: Both entities reported sole voting power and sole dispositive power over all 55,040 shares, with zero shared voting or dispositive power.
  • Triggering event date: The date of the event requiring the filing was July 1, 2026.
  • Funds disclosed: The filing states that "certain funds managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report."

Renaissance Technologies Discloses 2.35% Stake in Xenetic Biosciences

Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC"), both Delaware entities headquartered at 520 Madison Avenue, New York, New York 10022, filed Amendment No. 2 to a Schedule 13G covering common stock of Xenetic Biosciences, Inc. (NASDAQ:XBIO), par value $0.001 per share, CUSIP 984015602. The filing was signed by Brian Felczak, who serves as Chief Financial Officer of RTC and Vice President of RTHC, and is dated November 12, 2026.

According to the filing, each of the two reporting persons beneficially owns 55,040 shares, representing 2.35% of the class. The filing reports that all 55,040 shares are held with sole voting power and sole dispositive power, with no shared voting or dispositive power reported for either entity. The filing also discloses that certain funds managed by RTC hold the right to receive dividends and proceeds from the sale of the reported securities.

The filing was made under the passive investor provisions of the Schedule 13G framework. The certification included states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing designates RTC as an investment adviser (type "IA") and RTHC as a holding company (type "HC").

What Was Disclosed

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation disclosed beneficial ownership of 55,040 shares, or 2.35%, of Xenetic Biosciences common stock as of July 1, 2026, in Amendment No. 2 to their Schedule 13G filed November 12, 2026.